Literature DB >> 34370045

Deletion of heterogeneous nuclear ribonucleoprotein F in renal tubules downregulates SGLT2 expression and attenuates hyperfiltration and kidney injury in a mouse model of diabetes.

Kana N Miyata1,2, Chao-Sheng Lo1, Shuiling Zhao1, Xin-Ping Zhao1, Isabelle Chenier1, Michifumi Yamashita3, Janos G Filep4, Julie R Ingelfinger5, Shao-Ling Zhang6, John S D Chan7.   

Abstract

AIMS/HYPOTHESIS: We previously reported that renal tubule-specific deletion of heterogeneous nuclear ribonucleoprotein F (Hnrnpf) results in upregulation of renal angiotensinogen (Agt) and downregulation of sodium-glucose co-transporter 2 (Sglt2) in HnrnpfRT knockout (KO) mice. Non-diabetic HnrnpfRT KO mice develop hypertension, renal interstitial fibrosis and glycosuria with no renoprotective effect from downregulated Sglt2 expression. Here, we investigated the effect of renal tubular Hnrnpf deletion on hyperfiltration and kidney injury in Akita mice, a model of type 1 diabetes.
METHODS: Akita HnrnpfRT KO mice were generated through crossbreeding tubule-specific (Pax8)-Cre mice with Akita floxed-Hnrnpf mice on a C57BL/6 background. Male non-diabetic control (Ctrl), Akita, and Akita HnrnpfRT KO mice were studied up to the age of 24 weeks (n = 8/group).
RESULTS: Akita mice exhibited elevated systolic blood pressure as compared with Ctrl mice, which was significantly higher in Akita HnrnpfRT KO mice than Akita mice. Compared with Akita mice, Akita HnrnpfRT KO mice had lower blood glucose levels with increased urinary glucose excretion. Akita mice developed kidney hypertrophy, glomerular hyperfiltration (increased glomerular filtration rate), glomerulomegaly, mesangial expansion, podocyte foot process effacement, thickened glomerular basement membranes, renal interstitial fibrosis and increased albuminuria. These abnormalities were attenuated in Akita HnrnpfRT KO mice. Treatment of Akita HnrnpfRT KO mice with a selective A1 adenosine receptor inhibitor resulted in an increase in glomerular filtration rate. Renal Agt expression was elevated in Akita mice and further increased in Akita HnrnpfRT KO mice. In contrast, Sglt2 expression was increased in Akita and decreased in Akita HnrnpfRT KO mice. CONCLUSIONS/
INTERPRETATION: The renoprotective effect of Sglt2 downregulation overcomes the renal injurious effect of Agt when these opposing factors coexist under diabetic conditions, at least partly via the activation of tubuloglomerular feedback.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Akita mice; Angiotensinogen; Heterogeneous nuclear ribonucleoprotein F; Sodium-glucose co-transporter 2; Type 1 diabetes

Mesh:

Substances:

Year:  2021        PMID: 34370045      PMCID: PMC8992778          DOI: 10.1007/s00125-021-05538-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  46 in total

1.  Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.

Authors:  T Cooper Woods; Ryousuke Satou; Kayoko Miyata; Akemi Katsurada; Courtney M Dugas; Natasha C Klingenberg; Vivian A Fonseca; L Gabriel Navar
Journal:  Am J Nephrol       Date:  2019-03-28       Impact factor: 3.754

2.  Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice.

Authors:  Chao-Sheng Lo; Fang Liu; Yixuan Shi; Hasna Maachi; Isabelle Chenier; Nicolas Godin; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-28

3.  Heterogenous nuclear ribonucleoprotein F modulates angiotensinogen gene expression in rat kidney proximal tubular cells.

Authors:  Chih-Chang Wei; Deng-Fu Guo; Shao-Ling Zhang; Julie R Ingelfinger; John S D Chan
Journal:  J Am Soc Nephrol       Date:  2005-01-19       Impact factor: 10.121

4.  Activation of Na+/H+ exchanger NHE3 by angiotensin II is mediated by inositol 1,4,5-triphosphate (IP3) receptor-binding protein released with IP3 (IRBIT) and Ca2+/calmodulin-dependent protein kinase II.

Authors:  Peijian He; Janet Klein; C Chris Yun
Journal:  J Biol Chem       Date:  2010-06-28       Impact factor: 5.157

5.  Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

Authors:  Michael Freundlich; Yasmir Quiroz; Zhongyi Zhang; Yan Zhang; Yanauri Bravo; Jose R Weisinger; Yan Chun Li; Bernardo Rodriguez-Iturbe
Journal:  Kidney Int       Date:  2008-08-27       Impact factor: 10.612

6.  Histochemical evaluation of mouse and rat kidneys with lectin-horseradish peroxidase conjugates.

Authors:  B A Schulte; S S Spicer
Journal:  Am J Anat       Date:  1983-11

7.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

8.  Maternal diabetes modulates renal morphogenesis in offspring.

Authors:  Stella Tran; Yun-Wen Chen; Isabelle Chenier; John S D Chan; Susan Quaggin; Marie-Josée Hébert; Julie R Ingelfinger; Shao-Ling Zhang
Journal:  J Am Soc Nephrol       Date:  2008-02-27       Impact factor: 10.121

9.  SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

Authors:  Volker Vallon; Maria Gerasimova; Michael A Rose; Takahiro Masuda; Joseph Satriano; Eric Mayoux; Hermann Koepsell; Scott C Thomson; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-13

10.  Tubular Deficiency of Heterogeneous Nuclear Ribonucleoprotein F Elevates Systolic Blood Pressure and Induces Glycosuria in Mice.

Authors:  Chao-Sheng Lo; Kana N Miyata; Shuiling Zhao; Anindya Ghosh; Shiao-Ying Chang; Isabelle Chenier; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan
Journal:  Sci Rep       Date:  2019-10-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.